CStone and SteinCares Partner to Market and Commercialize Cancer Medication in Latin America
The deal allows for sugemalimab to be commercialized across 10 Latin America countries.
Stock.adobe.com
CStone Pharmaceuticals announced a partnership with SteinCares to market and commercialize cancer medication sugemalimab in multiple Latin American countries.1
Sugemalimab is a full-length anti-PD-L1 immunoglobulin G4 monoclonal antibody that has been approved by multiple health agencies across the globe to treat various types of tumors. The medication’s primary use is to be used in combination with chemotherapy, where it has been shown to reduce the risk of immunogenicity and toxicity.
CStone, the drug’s developer, previously announced similar deals with various pharmaceutical companies to expand sugemalimab into Europe, Southeast Asia, and Canada. SteinCares has a strong presence in Latin America, which is why it was selected for this partnership.
In a press release, CStone CEO, president of R&D, and executive director Dr. Jason Yang, said, “Following our successful market entries in Central and Eastern Europe, Switzerland, as well as the Middle East and Africa, we are excited to announce another key milestone in the global expansion of sugemalimab. As the first anti-PD-L1 monoclonal antibody approved in both the EU and UK for first-line, all-comer, Stage IV non-small cell lung cancer (NSCLC), sugemalimab is well-positioned for success in Latin America. SteinCares' extensive distribution network and deep marketing expertise will significantly enhance sugemalimab's reach.”
Yang continued, “We are also actively discussing with international partners in Western Europe, Southeast Asia, and Canada, while advancing regulatory submissions for additional indications of sugemalimab. We are confident that these efforts will further unlock the therapeutic and commercial potential of sugemalimab, ultimately benefiting patients worldwide."
In the same press release, SteinCares CEO Mitchell Waserstein added, “This agreement with CStone represents a significant step forward in our mission to create healthcare opportunities for patients in LATAM. At SteinCares, we are committed to providing more Latin Americans with greater access to safe, innovative, and affordable therapies. With our extensive experience and established sales network across the region, we are confident in our ability to successfully commercialize sugemalimab in LATAM and make a meaningful impact on patients' health and well-being."
SteinCares will control the commercialization rights for the drug in Brazil, Argentina, Chile, Colombia, Costa Rice, Panama, Peru, Guatemala, and Ecuador.
China’s National Medical Products Administration approved sugemalimab for certain cancer patients in June, 2022.2 At the time, Yang (who was the chief medical officer of CStone at the time) commented, “Dr. Jason Yang, Chief Medical Officer of CStone, said, "We are thrilled that sugemalimab has become the first anti- PD-1/PD-L1 monoclonal antibody approved for stage III NSCLC after concurrent or sequential chemoradiotherapy. The GEMSTONE-301 study has an innovative study design that enrolled patients with either concurrent or sequential chemoradiotherapy to better reflect real-world clinical practice and cover a broad patient population. We've also made significant progress in the registrational studies of sugemalimab in patients with esophageal squamous cell carcinoma, gastric cancer, and relapsed or refractory extranodal natural killer/T-cell lymphoma in a bid to benefit more cancer patients."
Sources
- CStone Partners with SteinCares to Market Sugemalimab in Latin America. CStone Pharmaceuticals. January 26, 2025. https://www.prnewswire.com/news-releases/cstone-partners-with-steincares-to-market-sugemalimab-in-latin-america-302360337.html
- CStone and Pfizer Announce NMPA Approval of Sugemalimab in Patients With Unresectable Stage III Non-Small Cell Lung Cancer. CStone Pharmaceuticals. June 6, 2022. Accessed January 27, 2025. https://www.prnewswire.com/news-releases/cstone-and-pfizer-announce-nmpa-approval-of-sugemalimab-in-patients-with-unresectable-stage-iii-non-small-cell-lung-cancer-301561552.html
Asembia 2025: Therapy Advancements Highlight Growing Cost and Access Concerns
April 30th 2025Fran Gregory, VP, emerging therapies, Cardinal Health, discusses the evolving cell and gene therapy landscape, highlighting pipeline growth, cost challenges, and emerging therapeutic areas beyond oncology and hematology.
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
FDA Approves AbbVie’s Rinvoq as First Oral JAK Inhibitor for Giant Cell Arteritis
April 30th 2025AbbVie secures FDA approval for Rinvoq as the first oral Janus kinase inhibitor indicated for giant cell arteritis, expanding its immunology portfolio and signaling strategic growth opportunities in underserved autoimmune markets.
